Experiences with
Mekinist14 public posts
Update on trametinib (Mekinist) for low grade serous ovarian cancer
Good morning everyone
We are delighted that NHS England has recommended that the MEK-inhibitor trametinib (Mekinist) should be routinely available as an off-label treatment option for adults with recurrent or progressive low grade serous ovarian cancer (LGSOC).
Want to take advantage of all our features? Just log in!
or
BRA/ Mek Treatment holiday flops in late stage melanoma trial
In the phase II study of over 200 patients, median progression-free survival (PFS) for those receiving intermittent dosing of dabrafenib (Tafinlar) and trametinib (Mekinist) was 5.5 months, as compared to 9.0 months for patients receiving continuous treatment (HR 1.36, 80% CI 1.10-1.66, P=0.063), reported
M is for Mekinist
His liver enzymes are too high, an indicator that liver tumors continue to increase in size or number
Because he is Wild type (V599 BRAF instead of the V600 genetic type) 2 docs have recommended trying Mekinist inhibitor only without the usual concomitant BRAF drug.
GREAT NEWS: HEALTH CANADA APPROVES FIRST ADJUVANT TREATMENT FOR MELANOMA TO PREVENT RELAPSE FOLLOWING SURGERY!
Health Canada has just approved the use of a combination therapy of Tafinlar® (dabrafenib) plus Mekinist® (trametinib) to prevent recurrence of melanoma following surgery in patients with a stage II or stage III diagnosis, also referred to as ‘adjuvant’ treatment.